United States · Wires & real time · PR Newswire

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

Published by PR Newswire · United States 1 h ago

SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative…

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading

Business Wire

Chamberlain University Opens First Utah Campus and 26th Location Nationwide, Expanding Nursing Education in the State with the Fewest Nurses per Capita

Associated Press (Business)

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Dow Jones Newswires

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

Share

Also worth reading

Chamberlain University Opens First Utah Campus and 26th Location Nationwide, Expanding Nursing Education in the State with the Fewest Nurses per Capita

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows